의약품 수탁판매 아웃소싱 시장

Pharmaceutical Contract Sales Outsourcing Market- Scope of Report

TMR's report on the global Pharmaceutical Contract Sales Outsourcing Marketstudies the past as well as the current growth trends and opportunities to gain valuable insights of the indicators of the Market during the forecast period from 2025 to 2035. The report provides revenue of the global Pharmaceutical Contract Sales Outsourcing Marketfor the period 2025 to 2035, considering 2025 as the base year and 2035 as the forecast year. The report also provides the compound annual growth rate (CAGR %) of the global Pharmaceutical Contract Sales Outsourcing Marketfrom 2025 to 2035.

The report has been prepared after an extensive research. Primary research involved bulk of the research efforts, wherein analysts carried out interviews with key opinion leaders, industry leaders, and opinion makers. Secondary research involved referring to key players' product literature, annual reports, press releases, and relevant documents to understand the Pharmaceutical Contract Sales Outsourcing Market .

Secondary research also included Internet sources, statistical data from government agencies, websites, and trade associations. Analysts employed a combination of top-down and bottom-up approaches to study various attributes of the global Pharmaceutical Contract Sales Outsourcing Market .

The report includes an elaborate executive summary, along with a snapshot of the growth behavior of various segments included in the scope of the study. Moreover, the report throws light on the changing competitive dynamics in the global Pharmaceutical Contract Sales Outsourcing Market . These serve as valuable tools for existing Market players as well as for entities interested in participating in the global Pharmaceutical Contract Sales Outsourcing Market .

The report delves into the competitive landscape of the global Pharmaceutical Contract Sales Outsourcing Market . Key players operating in the global Pharmaceutical Contract Sales Outsourcing Markethave been identified and each one of these has been profiled in terms of various attributes. Company overview, financial standings, recent developments, and SWOT are the attributes of players in the global Pharmaceutical Contract Sales Outsourcing Marketprofiled in this report.

Key Questions Answered in Global Pharmaceutical Contract Sales Outsourcing MarketReport:

• What are the opportunities in the global Pharmaceutical Contract Sales Outsourcing Market ?
• What are the major drivers, restraints, opportunities, and threats in the Market ?
• Which regional Market is set to expand at the fastest CAGR during the forecast period?
• Which segment is expected to generate the highest revenue globally in 2035?
• Which segment is projected to expand at the highest CAGR during the forecast period?
• What are the Market positions of different companies operating in the global Market ?

Pharmaceutical Contract Sales Outsourcing Market- Research Objectives and Research Approach

The comprehensive report on the global Pharmaceutical Contract Sales Outsourcing Marketbegins with an overview, followed by the scope and objectives of the study. The report provides detailed explanation of the objectives behind this study and key vendors and distributors operating in the Market and regulatory scenario for approval of products.

For reading comprehensibility, the report has been compiled in a chapter-wise layout, with each section divided into smaller ones. The report comprises an exhaustive collection of graphs and tables that are appropriately interspersed. Pictorial representation of actual and projected values of key segments is visually appealing to readers. This also allows comparison of the Market shares of key segments in the past and at the end of the forecast period.

The report analyzes the global Pharmaceutical Contract Sales Outsourcing Marketin terms of product, end-user, and region. Key segments under each criterion have been studied at length, and the Market share for each of these at the end of 2035 has been provided. Such valuable insights enable Market stakeholders in making informed business decisions for investment in the global Pharmaceutical Contract Sales Outsourcing Market .

Table of Contents

1. Preface

• 1.1. Market Definition and Scope
• 1.2. Market Segmentation
• 1.3. Key Research Objectives
• 1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Pharmaceutical Contract Sales Outsourcing Market

4. Market Overview

• 4.1. Introduction
  • 4.1.1. Segment Definition
• 4.2. Overview
• 4.3. Market Dynamics
  • 4.3.1. Drivers
  • 4.3.2. Restraints
  • 4.3.3. Opportunities
• 4.4. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, 2020 to 2035
  • 4.4.1. Market Revenue Projections (US$ Bn)

5. Key Insights

• 5.1. Healthcare Expenditure across Key Regions / Countries
• 5.2. Advantages of Pharmaceutical Sales Outsourcing
• 5.3. PORTER's Five Forces Analysis
• 5.4. PESTLE Analysis
• 5.5. Key Industry Events (Partnership, Collaborations, Product approvals, merger & acquisitions)

6. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, By Service Type

• 6.1. Introduction & Definition
• 6.2. Key Findings / Developments
• 6.3. Market Value Forecast By Service Type, 2020 to 2035
  • 6.3.1. Personal Promotion
    • 6.3.1.1. Promotional Sales Team
      • 6.3.1.1.1. Dedicated Sales Team
      • 6.3.1.1.2. Syndicated Sales Team
    • 6.3.1.2. Key Account Management
    • 6.3.1.3. Vacancy Management
  • 6.3.2. Non-Personal Promotion
    • 6.3.2.1. Tele-detailing
    • 6.3.2.2. Interactive E-Detailing
    • 6.3.2.3. Customer Service
    • 6.3.2.4. Medical Science Liaisons
    • 6.3.2.5. Patient Engagement Services
    • 6.3.2.6. Others
  • 6.3.3. Others
• 6.4. Market Attractiveness By Service Type

7. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, By Therapeutic Area

• 7.1. Introduction & Definition
• 7.2. Key Findings / Developments
• 7.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 7.3.1. Cardiovascular Disorders
  • 7.3.2. Oncological Disorders
  • 7.3.3. Respiratory Disorders
  • 7.3.4. Metabolic Disorders
  • 7.3.5. Neurological Disorders
  • 7.3.6. Orthopedic Disorders
  • 7.3.7. Infectious Diseases
  • 7.3.8. Others
• 7.4. Market Attractiveness By Therapeutic Area

8. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, By End-user

• 8.1. Introduction & Definition
• 8.2. Key Findings / Developments
• 8.3. Market Value Forecast By End-user, 2020 to 2035
  • 8.3.1. Pharmaceutical Companies
    • 8.3.1.1. Novel Drug Developers
    • 8.3.1.2. Generic Drug Developers
    • 8.3.1.3. Vaccine Developers
  • 8.3.2. Biotechnology Companies
• 8.4. Market Attractiveness By End-user

9. Global Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecasts, By Region

• 9.1. Key Findings
• 9.2. Market Value Forecast By Region
  • 9.2.1. North America
  • 9.2.2. Europe
  • 9.2.3. Asia Pacific
  • 9.2.4. Latin America
  • 9.2.5. Middle East & Africa
• 9.3. Market Attractiveness By Region

10. North America Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 10.1. Introduction
  • 10.1.1. Key Findings
• 10.2. Market Value Forecast By Service Type, 2020 to 2035
  • 10.2.1. Personal Promotion
    • 10.2.1.1. Promotional Sales Team
      • 10.2.1.1.1. Dedicated Sales Team
      • 10.2.1.1.2. Syndicated Sales Team
    • 10.2.1.2. Key Account Management
    • 10.2.1.3. Vacancy Management
  • 10.2.2. Non-Personal Promotion
    • 10.2.2.1. Tele-detailing
    • 10.2.2.2. Interactive E-Detailing
    • 10.2.2.3. Customer Service
    • 10.2.2.4. Medical Science Liaisons
    • 10.2.2.5. Patient Engagement Services
    • 10.2.2.6. Others
  • 10.2.3. Others
• 10.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 10.3.1. Cardiovascular Disorders
  • 10.3.2. Oncological Disorders
  • 10.3.3. Respiratory Disorders
  • 10.3.4. Metabolic Disorders
  • 10.3.5. Neurological Disorders
  • 10.3.6. Orthopedic Disorders
  • 10.3.7. Infectious Diseases
  • 10.3.8. Others
• 10.4. Market Value Forecast By End-user, 2020 to 2035
  • 10.4.1. Pharmaceutical Companies
    • 10.4.1.1. Novel Drug Developers
    • 10.4.1.2. Generic Drug Developers
    • 10.4.1.3. Vaccine Developers
  • 10.4.2. Biotechnology Companies
• 10.5. Market Value Forecast By Country, 2020 to 2035
  • 10.5.1. U.S.
  • 10.5.2. Canada
• 10.6. Market Attractiveness Analysis
  • 10.6.1. By Service Type
  • 10.6.2. By Therapeutic Area
  • 10.6.3. By End-user
  • 10.6.4. By Country

11. Europe Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 11.1. Introduction
  • 11.1.1. Key Findings
• 11.2. Market Value Forecast By Service Type, 2020 to 2035
  • 11.2.1. Personal Promotion
    • 11.2.1.1. Promotional Sales Team
      • 11.2.1.1.1. Dedicated Sales Team
      • 11.2.1.1.2. Syndicated Sales Team
    • 11.2.1.2. Key Account Management
    • 11.2.1.3. Vacancy Management
  • 11.2.2. Non-Personal Promotion
    • 11.2.2.1. Tele-detailing
    • 11.2.2.2. Interactive E-Detailing
    • 11.2.2.3. Customer Service
    • 11.2.2.4. Medical Science Liaisons
    • 11.2.2.5. Patient Engagement Services
    • 11.2.2.6. Others
  • 11.2.3. Others
• 11.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 11.3.1. Cardiovascular Disorders
  • 11.3.2. Oncological Disorders
  • 11.3.3. Respiratory Disorders
  • 11.3.4. Metabolic Disorders
  • 11.3.5. Neurological Disorders
  • 11.3.6. Orthopedic Disorders
  • 11.3.7. Infectious Diseases
  • 11.3.8. Others
• 11.4. Market Value Forecast By End-user, 2020 to 2035
  • 11.4.1. Pharmaceutical Companies
    • 11.4.1.1. Novel Drug Developers
    • 11.4.1.2. Generic Drug Developers
    • 11.4.1.3. Vaccine Developers
  • 11.4.2. Biotechnology Companies
• 11.5. Market Value Forecast By Country / Sub-region, 2020 to 2035
  • 11.5.1. Germany
  • 11.5.2. U.K.
  • 11.5.3. France
  • 11.5.4. Italy
  • 11.5.5. Spain
  • 11.5.6. Switzerland
  • 11.5.7. The Netherlands
  • 11.5.8. Rest of Europe
• 11.6. Market Attractiveness Analysis
  • 11.6.1. By Service Type
  • 11.6.2. By Therapeutic Area
  • 11.6.3. By End-user
  • 11.6.4. By Country / Sub-region

12. Asia Pacific Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 12.1. Introduction
  • 12.1.1. Key Findings
• 12.2. Market Value Forecast By Service Type, 2020 to 2035
  • 12.2.1. Personal Promotion
    • 12.2.1.1. Promotional Sales Team
      • 12.2.1.1.1. Dedicated Sales Team
      • 12.2.1.1.2. Syndicated Sales Team
    • 12.2.1.2. Key Account Management
    • 12.2.1.3. Vacancy Management
  • 12.2.2. Non-Personal Promotion
    • 12.2.2.1. Tele-detailing
    • 12.2.2.2. Interactive E-Detailing
    • 12.2.2.3. Customer Service
    • 12.2.2.4. Medical Science Liaisons
    • 12.2.2.5. Patient Engagement Services
    • 12.2.2.6. Others
  • 12.2.3. Others
• 12.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 12.3.1. Cardiovascular Disorders
  • 12.3.2. Oncological Disorders
  • 12.3.3. Respiratory Disorders
  • 12.3.4. Metabolic Disorders
  • 12.3.5. Neurological Disorders
  • 12.3.6. Orthopedic Disorders
  • 12.3.7. Infectious Diseases
  • 12.3.8. Others
• 12.4. Market Value Forecast By End-user, 2020 to 2035
  • 12.4.1. Pharmaceutical Companies
    • 12.4.1.1. Novel Drug Developers
    • 12.4.1.2. Generic Drug Developers
    • 12.4.1.3. Vaccine Developers
  • 12.4.2. Biotechnology Companies
• 12.5. Market Value Forecast By Country / Sub-region, 2020 to 2035
  • 12.5.1. China
  • 12.5.2. India
  • 12.5.3. Japan
  • 12.5.4. South Korea
  • 12.5.5. Australia & New Zealand
  • 12.5.6. Rest of Asia Pacific
• 12.6. Market Attractiveness Analysis
  • 12.6.1. By Service Type
  • 12.6.2. By Therapeutic Area
  • 12.6.3. By End-user
  • 12.6.4. By Country / Sub-region

13. Latin America Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 13.1. Introduction
  • 13.1.1. Key Findings
• 13.2. Market Value Forecast By Service Type, 2020 to 2035
  • 13.2.1. Personal Promotion
    • 13.2.1.1. Promotional Sales Team
      • 13.2.1.1.1. Dedicated Sales Team
      • 13.2.1.1.2. Syndicated Sales Team
    • 13.2.1.2. Key Account Management
    • 13.2.1.3. Vacancy Management
  • 13.2.2. Non-Personal Promotion
    • 13.2.2.1. Tele-detailing
    • 13.2.2.2. Interactive E-Detailing
    • 13.2.2.3. Customer Service
    • 13.2.2.4. Medical Science Liaisons
    • 13.2.2.5. Patient Engagement Services
    • 13.2.2.6. Others
  • 13.2.3. Others
• 13.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 13.3.1. Cardiovascular Disorders
  • 13.3.2. Oncological Disorders
  • 13.3.3. Respiratory Disorders
  • 13.3.4. Metabolic Disorders
  • 13.3.5. Neurological Disorders
  • 13.3.6. Orthopedic Disorders
  • 13.3.7. Infectious Diseases
  • 13.3.8. Others
• 13.4. Market Value Forecast By End-user, 2020 to 2035
  • 13.4.1. Pharmaceutical Companies
    • 13.4.1.1. Novel Drug Developers
    • 13.4.1.2. Generic Drug Developers
    • 13.4.1.3. Vaccine Developers
  • 13.4.2. Biotechnology Companies
• 13.5. Market Value Forecast By Country / Sub-region, 2020 to 2035
  • 13.5.1. Brazil
  • 13.5.2. Mexico
  • 13.5.3. Argentina
  • 13.5.4. Rest of Latin America
• 13.6. Market Attractiveness Analysis
  • 13.6.1. By Service Type
  • 13.6.2. By Therapeutic Area
  • 13.6.3. By End-user
  • 13.6.4. By Country / Sub-region

14. Middle East & Africa Pharmaceutical Contract Sales Outsourcing Market Analysis and Forecast

• 14.1. Introduction
  • 14.1.1. Key Findings
• 14.2. Market Value Forecast By Service Type, 2020 to 2035
  • 14.2.1. Personal Promotion
    • 14.2.1.1. Promotional Sales Team
      • 14.2.1.1.1. Dedicated Sales Team
      • 14.2.1.1.2. Syndicated Sales Team
    • 14.2.1.2. Key Account Management
    • 14.2.1.3. Vacancy Management
  • 14.2.2. Non-Personal Promotion
    • 14.2.2.1. Tele-detailing
    • 14.2.2.2. Interactive E-Detailing
    • 14.2.2.3. Customer Service
    • 14.2.2.4. Medical Science Liaisons
    • 14.2.2.5. Patient Engagement Services
    • 14.2.2.6. Others
  • 14.2.3. Others
• 14.3. Market Value Forecast By Therapeutic Area, 2020 to 2035
  • 14.3.1. Cardiovascular Disorders
  • 14.3.2. Oncological Disorders
  • 14.3.3. Respiratory Disorders
  • 14.3.4. Metabolic Disorders
  • 14.3.5. Neurological Disorders
  • 14.3.6. Orthopedic Disorders
  • 14.3.7. Infectious Diseases
  • 14.3.8. Others
• 14.4. Market Value Forecast By End-user, 2020 to 2035
  • 14.4.1. Pharmaceutical Companies
    • 14.4.1.1. Novel Drug Developers
    • 14.4.1.2. Generic Drug Developers
    • 14.4.1.3. Vaccine Developers
  • 14.4.2. Biotechnology Companies
• 14.5. Market Value Forecast By Country / Sub-region, 2020 to 2035
  • 14.5.1. GCC Countries
  • 14.5.2. South Africa
  • 14.5.3. Rest of Middle East & Africa
• 14.6. Market Attractiveness Analysis
  • 14.6.1. By Service Type
  • 14.6.2. By Therapeutic Area
  • 14.6.3. By End-user
  • 14.6.4. By Country / Sub-region

15. Competition Landscape

• 15.1. Market Player - Competition Matrix (By Tier and Size of companies)
• 15.2. Market Share Analysis By Company (2024)
• 15.3. Company Profiles
  • 15.3.1. IQVIA
    • 15.3.1.1. Company Overview
    • 15.3.1.2. Financial Overview
    • 15.3.1.3. Product Portfolio
    • 15.3.1.4. Business Strategies
    • 15.3.1.5. Recent Developments
  • 15.3.2. Axxelus
    • 15.3.2.1. Company Overview
    • 15.3.2.2. Financial Overview
    • 15.3.2.3. Product Portfolio
    • 15.3.2.4. Business Strategies
    • 15.3.2.5. Recent Developments
  • 15.3.3. EPS Corporation (EPS Holdings, Inc.)
    • 15.3.3.1. Company Overview
    • 15.3.3.2. Financial Overview
    • 15.3.3.3. Product Portfolio
    • 15.3.3.4. Business Strategies
    • 15.3.3.5. Recent Developments
  • 15.3.4. Syneos Health
    • 15.3.4.1. Company Overview
    • 15.3.4.2. Financial Overview
    • 15.3.4.3. Product Portfolio
    • 15.3.4.4. Business Strategies
    • 15.3.4.5. Recent Developments
  • 15.3.5. EVERSANA
    • 15.3.5.1. Company Overview
    • 15.3.5.2. Financial Overview
    • 15.3.5.3. Product Portfolio
    • 15.3.5.4. Business Strategies
    • 15.3.5.5. Recent Developments
  • 15.3.6. CMIC HOLDINGS Co., LTD.
    • 15.3.6.1. Company Overview
    • 15.3.6.2. Financial Overview
    • 15.3.6.3. Product Portfolio
    • 15.3.6.4. Business Strategies
    • 15.3.6.5. Recent Developments
  • 15.3.7. QFR Solutions
    • 15.3.7.1. Company Overview
    • 15.3.7.2. Financial Overview
    • 15.3.7.3. Product Portfolio
    • 15.3.7.4. Business Strategies
    • 15.3.7.5. Recent Developments
  • 15.3.8. Sales Focus Inc.
    • 15.3.8.1. Company Overview
    • 15.3.8.2. Financial Overview
    • 15.3.8.3. Product Portfolio
    • 15.3.8.4. Business Strategies
    • 15.3.8.5. Recent Developments
  • 15.3.9. GTS Solution
    • 15.3.9.1. Company Overview
    • 15.3.9.2. Financial Overview
    • 15.3.9.3. Product Portfolio
    • 15.3.9.4. Business Strategies
    • 15.3.9.5. Recent Developments
  • 15.3.10. Mercalis
    • 15.3.10.1. Company Overview
    • 15.3.10.2. Financial Overview
    • 15.3.10.3. Product Portfolio
    • 15.3.10.4. Business Strategies
    • 15.3.10.5. Recent Developments
  • 15.3.11. MaBiCo
    • 15.3.11.1. Company Overview
    • 15.3.11.2. Financial Overview
    • 15.3.11.3. Product Portfolio
    • 15.3.11.4. Business Strategies
    • 15.3.11.5. Recent Developments
  • 15.3.12. Mednext Pharmaceuticals Pvt. Ltd.
    • 15.3.12.1. Company Overview
    • 15.3.12.2. Financial Overview
    • 15.3.12.3. Product Portfolio
    • 15.3.12.4. Business Strategies
    • 15.3.12.5. Recent Developments
  • 15.3.13. Peak Pharma Solutions Inc.
    • 15.3.13.1. Company Overview
    • 15.3.13.2. Financial Overview
    • 15.3.13.3. Product Portfolio
    • 15.3.13.4. Business Strategies
    • 15.3.13.5. Recent Developments
  • 15.3.14. Promoveo Health
    • 15.3.14.1. Company Overview
    • 15.3.14.2. Financial Overview
    • 15.3.14.3. Product Portfolio
    • 15.3.14.4. Business Strategies
    • 15.3.14.5. Recent Developments
  • 15.3.15. Agilify Solutions Inc.
    • 15.3.15.1. Company Overview
    • 15.3.15.2. Financial Overview
    • 15.3.15.3. Product Portfolio
    • 15.3.15.4. Business Strategies
    • 15.3.15.5. Recent Developments